The insulin market in the U.S. is slated to open its doors come 2020, and Stefan Hendriks, Sandoz head of biopharmaceuticals, tells BioPharma-Reporter he expects the new competition to have a “significant” impact.
“When you introduce a biosimilar and you create that competitiveness then prices will go down, which is good for patients and for the healthcare system,” he says. “As a consequence of that, more patients will be able to afford to use their insulin or will get insulin — meaning millions more patients will be treated.”
Hendriks says while the U.S. market for biosimilars is lagging behind the European market, it’s beginning to gain momentum.
“The FDA has put in place some really good plans and good intentions to improve access — you also see other stakeholders playing a role,” he says. “So, we are positive about the evolution of the U.S. market.”
To read the full discussion on BioPharma-Reporter, click here.
